Eventually, we propose the combined application of JPX inhibitor Axitinib and PLAU inhibitor Palbociclib as a novel potential therapeutic strategy for the targeted treatment of HNSCC, which was also consistent with the HNSCC clinical therapeutic recommendation as the combination of EGFR and CDK4/6 inhibitors. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.